María Vanessa Pérez-Gómez

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies?

Pedro Magalhães, Martin Pejchinοvski, Katerina Markoska et al. · Scientific Reports · 2017 · 100 citations · Full text

Clarifying the concept of chronic kidney disease for non-nephrologists

María Vanessa Pérez-Gómez, Lorenz-Alexander Bartsch, Esmeralda Castillo-Rodríguez et al. · Clinical Kidney Journal · 2019 · 96 citations · Full text

Prevalence of protein-energy wasting syndrome and its association with mortality in haemodialysis patients in a centre in Spain.

Carolina Gracia-Iguacel, Emilio González‐Parra, María Vanessa Pérez-Gómez et al. · PubMed · 2013 · 87 citations